Autoimmune Hemolytic Anemia Clinical Trials

10 recruiting

Autoimmune Hemolytic Anemia Trials at a Glance

18 actively recruiting trials for autoimmune hemolytic anemia are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 1 with 4 trials, with the heaviest enrollment activity in Tianjin, Beijing, and Asyut. Lead sponsors running autoimmune hemolytic anemia studies include Institute of Hematology & Blood Diseases Hospital, China, University Hospital, Bordeaux, and Centre Hospitalier Universitaire Dijon.

Browse autoimmune hemolytic anemia trials by phase

Treatments under study

About Autoimmune Hemolytic Anemia Clinical Trials

Looking for clinical trials for Autoimmune Hemolytic Anemia? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Autoimmune Hemolytic Anemia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Autoimmune Hemolytic Anemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 118 of 18 trials

Recruiting
Early Phase 1

UCAR T-cell Therapy Targeting CD19/BCMA in Relapsed/Refractory Autoimmune Hemolytic Anemia

AIHA - Warm Autoimmune Hemolytic AnemiaUCART
The Second Hospital of Anhui Medical University15 enrolled1 locationNCT07530380
Recruiting
Early Phase 1

UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases

Autoimmune Hemolytic AnemiaEvans SyndromePrimary Immune Thrombocytopenic Purpura
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology27 enrolled1 locationNCT07441525
Recruiting

National Longitudinal Cohort of Hematological Diseases

Acute Myeloid LeukemiaMultiple MyelomaMyelodysplastic Syndrome+14 more
Institute of Hematology & Blood Diseases Hospital, China2,300 enrolled1 locationNCT04645199
Recruiting
Phase 1

Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

Relapsed/Refractory Systemic Lupus ErythematosusRelapsed/Refractory Systemic SclerosisRelapsed/Refractory Idiopathic Inflammatory Myopathies+3 more
Beijing Boren Hospital12 enrolled1 locationNCT07361094
Recruiting

French Registry of Adult Patients With Immune Thrombocytopenia and Autoimmune Hemolytic Anemia

Immune ThrombocytopeniaAutoimmune Hemolytic Anemia
University Hospital, Toulouse1,500 enrolled1 locationNCT02877706
Recruiting
Phase 2

Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a Prospective, Phase II, Randomized, Multicenter Study

Venous Thromboembolic DiseaseAutoimmune Hemolytic AnemiaProlonged Anticoagulation
Centre Hospitalier Universitaire Dijon72 enrolled1 locationNCT05089227
Recruiting
Phase 1Phase 2

A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia

Autoimmune Hemolytic AnemiaEvans SyndromeAutoimmune Cytopenia+1 more
Keymed Biosciences Co.Ltd158 enrolled3 locationsNCT07175493
Recruiting
Phase 1

OM336 in Autoimmune Cytopenias

ITP - Immune ThrombocytopeniaAIHA - Warm Autoimmune Hemolytic AnemiaAIHA - Cold Autoimmune Hemolytic Anemia
Ouro Medicines32 enrolled3 locationsNCT07083960
Recruiting
Early Phase 1

Safety Study of CC312 in Autoimmune Disease Patients

Rheumatoid Arthritis (RA)Autoimmune Hemolytic AnemiaSystemic Lupus Erythematosus (SLE)+3 more
CytoCares Inc18 enrolled1 locationNCT06888960
Recruiting
Not Applicable

Sirolimus in the Treatment of Refractory/Relapsed wAIHA

Warm Autoimmune Hemolytic Anemia
Peking Union Medical College Hospital22 enrolled1 locationNCT05925023
Recruiting

National Longitudinal Cohort of Hematological Diseases- Autoimmune Hemolytic Anemia

AIHA - Warm Autoimmune Hemolytic AnemiaAIHA - Cold Autoimmune Hemolytic AnemiaAutoimmune Hemolytic Anemia Mixed Type
Institute of Hematology & Blood Diseases Hospital, China9,999 enrolled1 locationNCT07019038
Recruiting

Biological Bank for the Patients Followed in a Constitutive Reference Center for Autoimmune Cytopenia

Immune ThrombocytopeniaAutoimmune Hemolytic AnemiaAutoimmune Neutropenia
University Hospital, Bordeaux200 enrolled1 locationNCT04005638
Recruiting
Phase 3

Second-line Treatment of Primary Autoimmune Hemolytic Anemia

Primary Autoimmune Hemolytic Anemia
Assiut University30 enrolled2 locationsNCT05057468
Recruiting
Phase 1

CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy.

Autoimmune Hemolytic AnemiaCD19/BCMA CAR T-cellsUniversal Allogeneic CAR T-cells
Institute of Hematology & Blood Diseases Hospital, China15 enrolled1 locationNCT06733610
Recruiting

Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia

Myelodysplastic SyndromesImmune ThrombocytopeniaAutoimmune Hemolytic Anemia+3 more
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico200 enrolled1 locationNCT05931718
Recruiting
Phase 2

Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA

Warm Autoimmune Hemolytic Anemia
Chen Miao22 enrolled1 locationNCT05922839
Recruiting
Phase 2

Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaAutoimmune Hemolytic Anemia+1 more
Gruppo Italiano Malattie EMatologiche dell'Adulto45 enrolled3 locationsNCT05694312
Recruiting

OBS'CEREVANCE: French Cohort of Pediatric Autoimmune Cytopenia

Immune ThrombocytopeniaAutoimmune Hemolytic AnemiaEvans Syndrome
University Hospital, Bordeaux3,500 enrolled9 locationsNCT05937828